-
Je něco špatně v tomto záznamu ?
Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation
RG Syljuasen, CS Sorensen, J Nylandsted, C Lukas, J Lukas, J Bartek
Jazyk angličtina Země Spojené státy americké
NLK
Free Medical Journals
od 1941 do Před 1 rokem
Freely Accessible Science Journals
od 1941 do Před 1 rokem
Open Access Digital Library
od 1941-01-01
Open Access Digital Library
od 1941-01-01
PubMed
15604269
Knihovny.cz E-zdroje
- MeSH
- apoptóza účinky léků fyziologie účinky záření MeSH
- buněčné jádro * účinky léků účinky záření MeSH
- G2 fáze * účinky léků účinky záření MeSH
- inhibitory proteinkinas * farmakologie MeSH
- lidé MeSH
- mitóza fyziologie účinky léků účinky záření MeSH
- nádorové buněčné linie MeSH
- nádory kostí enzymologie farmakoterapie patologie radioterapie MeSH
- osteosarkom enzymologie farmakoterapie patologie radioterapie MeSH
- proteinkinasy * metabolismus MeSH
- radiosenzibilizující látky farmakologie MeSH
- S fáze * účinky léků účinky záření MeSH
- viabilita buněk účinky záření MeSH
- Check Tag
- lidé MeSH
The human checkpoint kinase Chk1 has been suggested as a target for cancer treatment. Here, we show that a new inhibitor of Chk1 kinase, CEP-3891, efficiently abrogates both the ionizing radiation (IR)-induced S and G(2) checkpoints. When the checkpoints were abrogated by CEP-3891, the majority (64%) of cells showed fragmented nuclei at 24 hours after IR (6 Gy). The formation of nuclear fragmentation in IR-treated human cancer cells was directly visualized by time-lapse video microscopy of U2-OS cells expressing a green fluorescent protein-tagged histone H2B protein. Nuclear fragmentation occurred as a result of defective chromosome segregation when irradiated cells entered their first mitosis, either prematurely without S and G(2) checkpoint arrest in the presence of CEP-3891 or after a prolonged S and G(2) checkpoint arrest in the absence of CEP-3891. The nuclear fragmentation was clearly distinguishable from apoptosis because caspase activity and nuclear condensation were not induced. Finally, CEP-3891 not only accelerated IR-induced nuclear fragmentation, it also increased the overall cell killing after IR as measured in clonogenic survival assays. These results demonstrate that transient Chk1 inhibition by CEP-3891 allows premature mitotic entry of irradiated cells, thereby leading to accelerated onset of mitotic nuclear fragmentation and increased cell death.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14079621
- 003
- CZ-PrNML
- 005
- 20141119174219.0
- 007
- ta
- 008
- 141119s2004 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)15604269
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Syljuasen, R.G. $u Department of Cell Cycle and Cancer and Apoptosis Laboratory, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
- 245 10
- $a Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation / $c RG Syljuasen, CS Sorensen, J Nylandsted, C Lukas, J Lukas, J Bartek
- 520 9_
- $a The human checkpoint kinase Chk1 has been suggested as a target for cancer treatment. Here, we show that a new inhibitor of Chk1 kinase, CEP-3891, efficiently abrogates both the ionizing radiation (IR)-induced S and G(2) checkpoints. When the checkpoints were abrogated by CEP-3891, the majority (64%) of cells showed fragmented nuclei at 24 hours after IR (6 Gy). The formation of nuclear fragmentation in IR-treated human cancer cells was directly visualized by time-lapse video microscopy of U2-OS cells expressing a green fluorescent protein-tagged histone H2B protein. Nuclear fragmentation occurred as a result of defective chromosome segregation when irradiated cells entered their first mitosis, either prematurely without S and G(2) checkpoint arrest in the presence of CEP-3891 or after a prolonged S and G(2) checkpoint arrest in the absence of CEP-3891. The nuclear fragmentation was clearly distinguishable from apoptosis because caspase activity and nuclear condensation were not induced. Finally, CEP-3891 not only accelerated IR-induced nuclear fragmentation, it also increased the overall cell killing after IR as measured in clonogenic survival assays. These results demonstrate that transient Chk1 inhibition by CEP-3891 allows premature mitotic entry of irradiated cells, thereby leading to accelerated onset of mitotic nuclear fragmentation and increased cell death.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a apoptóza $x účinky léků $7 D017209
- 650 02
- $a apoptóza $x fyziologie $7 D017209
- 650 02
- $a apoptóza $x účinky záření $7 D017209
- 650 02
- $a nádory kostí $x enzymologie $x farmakoterapie $x patologie $7 D001859
- 650 02
- $a nádory kostí $x radioterapie $7 D001859
- 650 02
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a buněčné jádro $x účinky léků $x účinky záření $7 D002467
- 650 02
- $a viabilita buněk $x účinky záření $7 D002470
- 650 12
- $a G2 fáze $x účinky léků $x účinky záření $7 D016195
- 650 02
- $a lidé $7 D006801
- 650 02
- $a mitóza $x fyziologie $x účinky léků $x účinky záření $7 D008938
- 650 02
- $a osteosarkom $x enzymologie $x farmakoterapie $7 D012516
- 650 02
- $a osteosarkom $x patologie $x radioterapie $7 D012516
- 650 12
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 12
- $a proteinkinasy $x metabolismus $7 D011494
- 650 02
- $a radiosenzibilizující látky $x farmakologie $7 D011838
- 650 12
- $a S fáze $x účinky léků $x účinky záření $7 D016196
- 700 1_
- $a Sorensen, C.S.
- 700 1_
- $a Nylandsted, J.
- 700 1_
- $a Lukas, C.
- 700 1_
- $a Lukáš, Jiří $7 xx0094305
- 700 1_
- $a Bártek, Jiří, $d 1953- $7 xx0046271
- 773 0_
- $t Cancer Research $x 0008-5472 $g Roč. 64, č. 24 (2004), s. 9035-9040 $p Cancer Res $w MED00009437
- 773 0_
- $p Cancer Res $g 64(24):9035-40, 2004 Dec 15 $x 0008-5472
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20141119172528 $b ABA008
- 991 __
- $a 20141119174259 $b ABA008
- 999 __
- $a ok $b bmc $g 1047956 $s 878640
- BAS __
- $a 3
- BMC __
- $a 2004 $b 64 $c 24 $d 9035-9040 $x MED00009437 $i 0008-5472 $m Cancer research $n Cancer Res
- LZP __
- $a NLK 2014-1/lp